skip to main content

PSMA Discordance — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersPSMA DiscordanceSCE Medical Oncology

A man with PSMA-positive metastatic castration-resistant prostate cancer has progressed after enzalutamide. He has not received a taxane, and the MDT considers it clinically appropriate to delay taxane chemotherapy. Which statement matches the current UK Pluvicto SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — This is now a licensed Pluvicto setting, after PSMA imaging confirms eligibility

Explanation lettering: B = shown as A · A = shown as B · E = shown as C · C = shown as D · D = shown as E

B is correct: the current SmPC includes PSMA-positive mCRPC after ARPI progression when delaying taxane is appropriate. A wrongly makes any taxane-naive patient ineligible; C invents a two-taxane minimum; D substitutes the wrong mandated selection modality; E is wrong because radioligand therapy does not reverse the need to maintain castration. NHS commissioning criteria must still be checked separately from the licence.

Reference: Pluvicto UK summary of product characteristics (Updated 14 July 2026): https://www.medicines.org.uk/emc/product/13965/smpc